Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 December 2003Website:
http://www.meipharma.comNext earnings report:
26 September 2024Last dividends:
16 November 2023Next dividends:
N/APrice
regular market | Mon, 01 Jul 2024 13:30:00 GMTAnalysts recommendations
Institutional Ownership
MEIP Latest News
MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $1.66 per share versus the Zacks Consensus Estimate of a loss of $1.46. This compares to earnings of $1.60 per share a year ago.
MEI Pharma, Inc. (MEIP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MEI Pharma, Inc. (NASDAQ:MEIP ) Q4 2023 Earnings Call Transcript September 26, 2023 5:00 PM ET Company Participants David Walsey - SVP, Corporate Affairs David Urso - President & CEO Jay File - CFO Richard Ghalie - CMO Conference Call Participants Yale Jen - Laidlaw & Company Stephen Willey - Stifel Operator Good day and welcome to the MEI Fiscal Year-End Earnings Call. My name is Gary and I will be the conference facilitator today.
MEI Pharma, Inc. (MEIP) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $2.60. This compares to loss of $3.40 per share a year ago.
What type of business is MEI Pharma?
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
What sector is MEI Pharma in?
MEI Pharma is in the Healthcare sector
What industry is MEI Pharma in?
MEI Pharma is in the Biotechnology industry
What country is MEI Pharma from?
MEI Pharma is headquartered in United States
When did MEI Pharma go public?
MEI Pharma initial public offering (IPO) was on 18 December 2003
What is MEI Pharma website?
https://www.meipharma.com
Is MEI Pharma in the S&P 500?
No, MEI Pharma is not included in the S&P 500 index
Is MEI Pharma in the NASDAQ 100?
No, MEI Pharma is not included in the NASDAQ 100 index
Is MEI Pharma in the Dow Jones?
No, MEI Pharma is not included in the Dow Jones index
When does MEI Pharma report earnings?
The next expected earnings date for MEI Pharma is 26 September 2024